ArticlePsychopharmacology2026
Dissociation between the dynamics of symptom scores and network metrics in psychosis treatment: a proof-of-concept study using network intervention analysis.
Article in Psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
rationaleAntipsychotic efficacy in schizophrenia spectrum disorders (SSD) is commonly evaluated using static measures that fail to capture the dynamic evolution of symptoms and the unfolding impact of treatment over time. Network intervention analysis (NIA) is a novel approach that models pharmacological treatments as active nodes within longitudinal symptom networks.
objectivesThis proof-of-concept study aimed to contrast the information about antipsychotic-symptom interactions provided using NIA with that using a simple time-based analysis of symptom progression. We hypothesised that while overall symptom improvement would be similar across pharmacological profiles, the symptom decoupling patterns (connection density) extracted from NIA would differ significantly. We also hypothesised that the rate of change for the decoupling would be significantly dissociated from the rate of change for the clinical symptoms.
methodsPatients with SSD underwent weekly symptom evaluation over six weeks. NIA was used to characterise the evolving impact of treatment with three distinct drug classes: muscarinic, serotonergic/dopaminergic, and adrenergic/low dopaminergic. Standardised slopes from NIA density regression models and symptom mixed-effect models were directly compared using a robust non-parametric bootstrap procedure.
resultsNIA density analysis showed a significant time*group interaction, (p = 0.016) which was not observed in symptom severity trajectories. The slope for density reduction was steeper than the slope for symptom severity reduction (Δβ̂=0.426, p = 0.002). For each receptor profile class, the treatment node within the NIA demonstrated distinct patterns of association with symptoms.
conclusionsThese findings highlight the potential of NIA to capture the evolving interaction between antipsychotic classes and dynamic symptom trajectories in SSD.
Indexed as
Identifiers
42178405What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.